吗替麦考酚酯治疗IgA肾病后的组织学变化
结果显示MMF治疗后毛细血管内皮细胞增生和细胞/纤维细胞性新月体的肾小球百分比显著改善,系膜IgA沉积显著减少,且组织学改善在停药后持续,血肌酐3年随访稳定。
要点
- MMF治疗与IgA肾病患者组织病理学改善相关。
- 毛细血管内皮细胞增生和细胞/纤维细胞性新月体显著改善。
- 组织学改善在停药后持续,提示2年治疗足够获益。
核心结论
- MMF治疗与IgA肾病患者的组织病理学改善相关。
主要发现
- MMF治疗后重复活检显示毛细血管内皮细胞增生和细胞/纤维细胞性新月体的肾小球平均百分比显著改善。
- 系膜细胞增生、节段性硬化或肾小管萎缩评分无变化。
- 系膜IgA沉积显著减少。
- 组织病理学改善在停止MMF治疗后持续。
- 3年随访时中位血清肌酐稳定在104 µmol/L(IQR 79-147)。
关键数值与推荐
- 诊断时中位年龄35岁(IQR 30-41),血清肌酐97 µmol/L(IQR 79-153),UPCR 146 mg/mmol(IQR 98-212)。
- 两次活检中位间隔24个月(范围9-41)。
临床怎么用
- 对于有毛细血管内皮细胞增生组织学证据的IgA肾病患者,可考虑使用MMF治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endocapillary hypercellularity independently predicts renal outcome in immunoglobulin A nephropathy (IgAN). Mycophenolate mofetil (MMF) treatment is offered to patients presenting to the Imperial College Renal and Transplant Centre with IgAN and histological evidence of endocapillary hypercellularity. Clinical trials of MMF in IgAN have been inconclusive and have been limited by a lack of specific histological inclusion and exclusion criteria when recruiting patients. Evidence of histological improvement following MMF treatment would support its therapeutic use. We therefore reviewed histological changes after MMF therapy in a cohort of IgAN patients. METHOD: Eighteen IgAN patients with native renal biopsies before and after repeated MMF treatment were identified. Patients were excluded if they had received any other immunosuppressive therapy, including corticosteroids. On the basis of the Oxford Classification of IgAN, we reviewed histological changes after MMF treatment. RESULTS: Nine patients (50%) were male. At diagnostic renal biopsy, the median age was 35 years [interquartile range (IQR) 30-41], serum creatinine was 97 µmol/L (IQR 79-153) and urine protein creatinine ratio (UPCR) was 146 mg/mmol (IQR 98-212). The median time between biopsies was 24 months (range 9-41). Following MMF treatment, repeat biopsy demonstrated statistically significant improvement in the mean percentage of glomeruli showing endocapillary hypercellularity and cellular/fibrocellular crescents. There was no change in mesangial hypercellularity, segmental sclerosis or tubular atrophy scores. Mesangial IgA deposition was also significantly reduced. Histopathological improvement persisted after the cessation of MMF therapy, suggesting that 2 years of treatment is adequate for benefit. The median serum creatinine remained stable at 3 years follow-up at 104 µmol/L (IQR 79-147). CONCLUSION: MMF treatment is associated with histopathological improvement in IgAN.
引用
- Beckwith H, Medjeral-Thomas N, Galliford J, et al. Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrol Dial Transplant. 2017. PMID: 28391339. doi:10.1093/ndt/gfw326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。